Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo

Blood

Volumn 109, Issue 5, 2007, Pages 1992-1997

  Nishimura, Toshihiko ^a,b   Myles, Timothy ^a,b   Piliposky, Adrian M ^a,b   Kao, Peter N ^a,b   Berry, Gerald J ^a,b   Leung, Lawrence L K ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; CYTOKINE; MUTANT PROTEIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLITIS; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT;

EID: 33847357422     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-012567     Document Type: Article

References (43)

1. Walport MJ. Complement. N Engl J Med, 2001;344:1058-1066.
2. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-852.
3. Haviland DL, McCoy RL, Whitehead WT, et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol. 1995;154:1861-1869.
4. Schieferdecker HL, Schlaf G, Jungermann K, Gotze O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol. 2001;1:469-481.
5. Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2002;110:101-108.
6. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defense to infection. Nature. 1996;383:86-89.
7. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem. 1989;27:277-285.
8. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun. 1989;162:933-939.
9. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1999;266:21833-21838.
10. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
11. Tan AK, Eaton DL. Activation and characterization of pro-carboxypeptidase B from human plasma. Biochemistry. 1995;34:5811-5816.
12. Esmon CT. The protein C pathway. Chest. 2003;124:26S-32S.
13. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
14. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-430.
15. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96:2534-2538.
16. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
17. Broze G, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
18. Shinohara T, Sakurada C, Suzuki T, et al. Procarboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol. 1994;103:400-404.
19. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 2002;46:131-134.
20. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278:51059-51067.
21. Asai S, Sato T, Tada T, et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol. 2004;173:4669-4674.
22. Heuertz RM, Ahmed N, Webster RO. Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J Immunol. 1996;156:3412-3417.
23. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378:413-416.
24. Tsiang M, Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry. 1996;35:16449-16457.
25. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621.
26. Lira SA, Zalamea P, Heinrich JN, et al. Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. J Exp Med. 1994;180:2039-2048.
27. Yamashiro S, Wang J-M, Yang D, Gong W-H, Kamohara H, Yoshimura T. Expression of CCR6 and CD38 by cytokine-activated human neutrophils. Blood. 2000;96:3958-3963.
28. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood. 2004;103:2196-2204.
29. Nagashima M, Yin ZF, Zhao L, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest. 2002;109:101-110.
30. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest. 2002;110:1275-1282.
31. Renckens R, Roelofs JTH, ter Horst SAJ, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol. 2005;175:6764-6771.
32. Wagers SS, Norton RJ, Rinaldi LM, Bates JHT, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest. 2004;114:104-111.
33. Strey CW, Markiewski M, Mastellos D, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003;198:913-923.
34. Markiewski MM, Mastellos D, Tudoran R, et al. C3a and C5a activation products of the third component complement (C3) are critical for normal liver recovery after toxic injury. J Immunol. 2004;173:747-754.
35. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
36. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001;276:11199-11203.
37. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
38. Esmon CT. Is APC activation of endothelial cell PAR1 important in severe sepsis?: No. J Thromb Haemost. 2005;3:1910-1911.
39. Ruf W. Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. J Thromb Haemost. 2005;3:1912-1914.
40. Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg. 2005;129:423-428.
41. Leung LLK, Gibbs CS. Modulation of thrombin's procoagulant and anticoagulant properties. Thromb Haemost. 1997;78:577-580.
42. Cantwell AM, Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem. 2000;275:39827-39830.
43. Gruber A, Cantwell AM, DiCera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 2002;277:27581-27584.